ABIVAX Société Anonyme
ABVX
$5.94
$0.020.34%
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
--
Headlines
3/14/2025
-
MarketBeat
3/7/2025
-
MarketBeat
2/27/2025
-
Zacks Investment Research
2/25/2025
-
TipRanks Financial Blog
2/21/2025
-
GuruFocus
2/21/2025
-
Globe Newswire
2/17/2025
-
MarketBeat
2/13/2025
-
TipRanks Financial Blog
2/11/2025
-
Zacks Investment Research
2/10/2025
-
MarketBeat
2/5/2025
-
The Fly
Here's Why Abivax SA Sponsored ADR (ABVX) is Poised for a Turnaround After Losing -19.81% in 4 Weeks
1/30/2025
-
Zacks Investment Research
1/28/2025
-
TipRanks Financial Blog
1/28/2025
-
TipRanks Financial Blog
1/28/2025
-
GuruFocus
1/28/2025
-
Globe Newswire
1/27/2025
-
TipRanks Financial Blog
1/23/2025
-
GuruFocus
1/23/2025
-
Globe Newswire
1/23/2025
-
MarketBeat
1/15/2025
-
MarketBeat
1/12/2025
-
TipRanks Financial Blog
1/10/2025
-
MarketBeat
1/9/2025
-
TipRanks Financial Blog
1/9/2025
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, September 9, 2024
Period Date
Sunday, June 30, 2024
Next Filing
Beginning of April (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
33 1 53 83 09 63
Address
7-11 boulevard Haussmann
Paris, 75009
Paris, 75009
Country
Year Founded
Business Description
Sector
--
Industry
--
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in...
more